AMRI has acquired the new MALDI PharmaPulse system from
"We see incredible potential for this technology at
With technical support from these partners, AMRI will apply advanced laboratory automation and MS technologies to provide next generation, high throughput, label-free screening by MS (PharmaPulse). These improved assays and screening strategies will accelerate and enable development of drugs to treat complex diseases that are poorly served by current therapies. AMRI will apply its biological understanding and expertise to extend the utility of MALDI PharmaPulse technology to encompass complex cell-based assays and an expanded portfolio of MS-based biochemical assays.
"The protocols we can develop by applying the latest MS technologies to assay development have enormous potential for many disease areas, including such challenging areas as Alzheimer's disease and other neurological diseases," said
"The MALDI PharmaPulse (MPP) solution is a game-changer for high throughput drug screening," said
Pharmaceutical companies require high throughput assay technologies to identify "Hits", the drug development starting points, from large collections of compounds. MALDI PharmaPulse systems combine Bruker's MALDI-TOF mass spectrometers with high throughput robotics and software from HighRes Biosolutions. The combination provides the first MS-based screening system able to screen > 10,000 test samples per day in Hit discovery mode and complete Hit discovery in a timely, cost effective manner using MS technology. AMRI has targeted a throughput of 100,000 test samples per day to match the requirements of clients refusing to compromise on screen quality.
Connect with the AMRI team at SLAS, from
AMRI Forward-Looking Statements
This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements regarding the potential benefits of mass spectrometry-based screening technology and its impact on drug discovery, AMRI's ability to leverage such technology, the expected demand from customers and the potential benefit to AMRI's Discovery and Development Services business. Readers should not place undue reliance on these forward-looking statements. AMRI's actual results may differ materially from such forward-looking statements as a result of numerous factors, some of which AMRI may not be able to predict and may not be within AMRI's control. Factors that could cause such differences include, but are not limited to, the ability of AMRI to hire and retain qualified biologists to develop assay protocols using the mass spectrometry-based screening technology, the risk of a decrease in customers' demand for AMRI's drug discovery research services, as well as those risks discussed in AMRI's Annual Report on Form 10-K for the year ended
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/amri-announces-strategic-alliance-to-advance-mass-spectrometry-capabilities-for-drug-discovery-300403186.html
News Provided by Acquire Media